Benigno C. Valdez and his fellow researchers, Apostolia M. Tsimberidou, Bin Yuan, Yago Nieto, Mehmet A. Baysal, Abhijit Chakraborty, Clark R. Andersen, and Borje S. Andersson, delve into a groundbreaking triple-drug combination against pancreatic cancer. They reveal how the synergistic effects of histone deacetylase inhibitors, PARP inhibitors, and decitabine can enhance treatment efficacy. This innovative strategy challenges conventional therapies and highlights the importance of collaboration in advancing personalized cancer treatment.